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Genetic diagnosis in families with inherited platelet disorders (IPD) is not performed 
widely because of the genetic heterogeneity of this group of disorders and because 
in most cases, it is not possible to select single candidate genes for analysis using 
clinical and laboratory phenotypes. Next generation sequencing (NGS) technology 
has revolutionised the scale and cost-effectiveness of genetic testing, and has 
emerged as a valuable tool for IPD. This review examines the potential utility of NGS 
as a diagnostic tool to streamline detection of causal variants in known IPD genes 
and as a vehicle for new gene discovery.	
	
MAIN TEXT	
Genetic diagnosis for families with inherited bleeding disorders may enhance clinical 
care by improving the precision of diagnosis, by enabling better prediction of 
prognosis and heritability and by informing selection of targeted therapies. Although 
widely available for coagulation factor disorders such as haemophilia, genetic testing 
for inherited platelet disorders (IPD) has until recently, been restricted to a small 
number of specific disorders.  
 
Scope of inherited platelet disorders 
One important difference between IPD and coagulation factor disorders is that the 
IPD comprise a highly heterogeneous group of different disorders of platelet number 
or function. Recent advances in gene discovery have now defined more than 50 
distinct IPD (tables 1 and 2). Most of these disorders have been reported in small 
numbers of families worldwide, suggesting that they are individually rare. However, 
IPD collectively account for nearly 10% of all bleeding disorders in some national 
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registries [1], and may be substantially under-reported. Despite the prevalence of 
IPD, diagnosis at genetic level is achieved in a small minority of families and is 
usually restricted to centres where there is a clinical or research interest in platelet 
disorders [2]. For many families with IPD, absence of genetic diagnosis reflects the 
practical constraint that traditional genetic testing by analysis of single candidate 
genes cannot be applied to most IPD in which multiple genes are potentially 
implicated. Causal variants may lies in non-coding regions implicated in the 
regulation of known IPD candidate genes but which have not been historically 
examined in clinical diagnostic genetic testing, or may occur in more than one IPD 
gene giving rise to complex inheritance patterns and practical difficulties in resolving 
phenotypes. In other IPD families, failure to achieve genetic diagnosis is very likely 
to reflect that they harbour causal variants in novel genes, not yet associated with 
platelet disorders.  
 
Inherited thrombocytopenia as a model for improving genetic diagnosis 
Amongst the IPD, the potential for genetic diagnosis is best illustrated by the 
inherited thrombocytopenias. In this group of disorders, molecular testing has 
historically focussed on the recessive forms of Bernard Soulier syndromes (BSS), 
caused by variants in GP1BA, GP1BB or GP9, which may be associated with a 
severe bleeding tendency. However, recessive BSS accounts for only approximately 
5% of inherited thrombocytopenia cases in large series [3]. More recently, good 
progress has been made by several large international consortia on unravelling 
genetic defects associated with inherited thrombocytopenias with less severe 
bleeding and which are often discovered as an incidental finding during routine 
haematology testing. With these advances, comprehensive genetic testing has now 
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been reported to enable molecular diagnosis in up to 50% of patients with the 
inherited thrombocytopenia phenotype [4]. These analyses have demonstrated that 
the majority of families with inherited thrombocytopenia for which genetic diagnosis 
is currently possible, have causal variants in MYH9, ANKRD26, ACTN1 and 
heterozygous forms of BSS. The reminder of inherited thrombocytopenia families 
have rare disorders described in small numbers of pedigrees worldwide, or have 
unknown disorders [4] 
 
The inherited thrombocytopenias also illustrate how genetic diagnosis can directly 
benefit affected families. Although in many cases, the haemostatic defect in inherited 
thrombocytopenias is small or even absent, this is not necessarily the case for other 
phenotypic manifestations for which genetic diagnosis can have important prognostic 
implications. This is best illustrated by inherited thrombocytopenias caused by some 
variants in RUNX1 or ANKR26, which are associated with an increased risk of 
myeloid malignancy [5] or by some ETV6 variants that may be associated with 
lymphoid malignancy [6]. Similarly, demonstration of some MYH9 variants in families 
with MYH9-related disorder may be predictive of adverse phenotypes such as 
hearing loss, cataract formation and rapidly progressive nephropathy that may not be 
clinically evident in very young affected patients [7], and which may require specific 
interventions. Detection of causal variants for some inherited thrombocytopenias 
may also enable specific treatments such as thrombopoietin mimetics to increase 
platelet counts in settings such as before surgery. These agents have proven 
efficacy in disorders such as MYH9-related disorder [8] and Wiscott Aldrich 
syndrome [9], but are of uncertain or doubtful benefit in other inherited 
thrombocytopenias.  
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Approaches to gene sequencing in inherited platelet disorders 
Sanger sequencing remains the gold standard for genetic testing in human disease, 
but requires amplification of discrete regions of candidate genes by polymerase 
chain reaction and then sequencing by chain termination techniques. Since this is a 
time-consuming and low-throughput approach, Sanger sequencing is practically 
limited to the small number of IPD in which candidate genes can be selected by 
laboratory phenotype testing (eg. Glanzmann thrombasthenia (ITGA2B or ITGB3) or 
because there are additional syndromic feature that are suggestive of a specific IPD 
(eg. MYH9- related disorder (MYH9) and Chediak Higashi syndrome (LYST)). 
 
Next generation DNA sequencing (NGS) technology is a significant advance from 
Sanger sequencing that has revolutionised gene discovery and is now emerging as a 
clinical diagnostic tool for IPD. This technique enables parallel sequencing of large 
regions of DNA spanning many genes, is rapid and readily automated and is an 
increasingly cost effective method of achieving a genetic diagnosis. 
 
One important application of NGS as a diagnostic tool for IPD and other bleeding 
disorders has been the development of NGS panels that enable analysis of pre-
defined groups of genes already implicated in human bleeding and platelet 
disorders. This has been recently illustrated by the ThromboGenomics NGS 
platform, which enables rapid and cost-effective sequence analysis of the coding 
regions and selected non-coding regions of 63 genes relevant to bleeding disorders, 
including 36 genes previously associated with IPD [10]. In a recent validation study 
in which 300 DNA samples from patients with IPD and other bleeding disorders, the 
ThromboGenomics platform showed 100% sensitivity for detecting causal variants in 
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samples in which genetic diagnosis had already been obtained by Sanger 
methodology. Genetic diagnosis was also achieved in more than 90% of cases with 
a phenotypically suspected disorder, but who had not undergone prior genetic 
analysis [10]. 
	
Gene discovery in inherited platelet disorders	
In circumstances when analysis of a single candidate gene or gene panels does not 
yield a plausible genetic explanation for an IPD, NGS may also be an effective 
means of identifying causal variants in genes not previously associated with IPD. 
This typically requires extending the target regions for NGS analysis to the exonic 
regions of all protein coding genes (whole exome sequencing; WES) and has been 
adopted by several large scale gene discovery projects, including the UK Genotyping 
and Platelet Phenotyping (GAPP) [11] and the international BRIDGE-Bleeding and 
Platelet Disorders (BRIDGE-BPD) [12] programmes. These groups and others have 
achieved notable successes with WES, resulting in the discovery and 
characterisation of several new IPD (reviewed in [13]) 
 
Further advances in NGS technology have also now extended the scope of cost-
effective sequencing from exome to whole genome level (whole genome 
sequencing; WGS). Current WGS techniques enable analysis of more than 98% of 
all genomic DNA with sufficient confidence to reliably detect sequence variants. This 
is essential to enable detection of some IPD in which the causal variants occur in 
regulatory regions outside the coding space, such as thrombocytopenia absent 
radius syndrome (RBM8A) [14] and ANKRD26-related thrombocytopenia 
(ANKRD26) [15]. WGS has recently been used to successfully identify SRC as a 
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new candidate gene for an IPD associated with thrombocytopenia associated with 
myelofibrosis and skeletal abnormalities [16]. 
 
Identification of causal variants for IPD from next generation sequencing data 
Although WES and WGS dramatically increase the potential for gene discovery and 
genetic diagnosis in IPD, there are also some practical barriers for clinical delivery of 
these approaches. Chief amongst these is that even at exome level, sequence data 
from individual patients may show greater than 15,000 differences across the 
estimated 20,000 to 25,000 protein coding genes, compared to reference exome 
sequences. This may raise significant challenges in resolving variants in a single 
gene that are causally associated with an IPD from irrelevant bystander variants that 
are unrelated to the IPD.  
 
One way of overcoming this barrier is to compare candidate sequence variants in 
IPD families against publicly available databases that record previously identified 
disease-associated variants. Examples of these resources include ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/), the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/) and the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk), although it is essential to recognise that some variants 
listed in public resources may be identified as ‘disease-associated’, but are in fact 
bystander variants without functional consequences [17].  
 
For variants not previously associated with IPD, many can be eliminated from further 
consideration by applying the assumption that variants that are common in the 
background population of the IPD case are unlikely to be causally associated with a 
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rare IPD. This filtering step is now more reliable since the publication of catalogues 
of population genetic variation through initiatives such as the UK10K project [18] and 
NHLBI exome sequencing project (http://evs.gs.washington.edu/EVS/), which 
provide increasingly refined estimates of the population frequencies of variants that 
are specific to ethnicity, and which can be used to assess rarity of candidate variants 
in IPD families. Variants that are predicted to have a high impact on gene translation 
(stop-gain, stop-loss, frame shift or splice donor/acceptor site) and missense variants 
are more commonly disease-associated than synonymous or non-coding region 
variants. Therefore, further refinement of candidate gene lists may sometimes be 
achieved by annotation of variants against likely gene transcripts and elimination of 
those with low predicted impact. More detailed predictions of the likely pathogenicity 
of missense variants may also be achieved using publically available computational 
algorithms such as the Combined Annotation Dependent Depletion (CADD) score 
(http://cadd.gs.washington.edu). Demonstration that a candidate variant segregates 
with the IPD phenotype within family structures may provide further support of 
causality. 
 
Using phenotype to resolve causal IPD variants 
Detailed analysis of the phenotype of individual IPD families is also a powerful tool to 
refine further the selection of candidate variants. This approach has been most 
successful for platelet function disorders in which careful laboratory identification of 
the defective platelet pathway can be used to narrow down variant lists to genes 
functionally implicated in specific platelet pathways, as illustrated by the recent 
discovery of SLFN14 as a candidate gene for an IPD in which platelet secretion is 
defective [19]. 
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For most IPD in which there are less distinctive features, there is still potential value 
in considering phenotype, but in conjunction with statistical genetic techniques to 
increase the power of resolving candidate variants. This has been best illustrated by 
the international BRIDGE-BPD consortium 
(https://bridgestudy.medschl.cam.ac.uk/bpd.shtml), in which a collection of more 
than 1000 patients with bleeding disorders or IPD has undergone detailed phenotype 
coding and either WES or WGS analysis. An essential part of this programme has 
been the systematic description of the clinical and laboratory characteristics of 
participants using the Human Phenotype Ontology (HPO) vocabulary, which has 
been updated comprehensively with terms for bleeding and platelet disorders [12]. 
This enables statistical analysis of the degree of similarity of phenotype terms 
between unrelated families and thereby, identification of causal variants for IPD by 
comparing WES or WGS datasets in families with a high degree of similarity. The 
efficacy of this approach is illustrated by the recent discovery of DIAPH1 as a new 
IPD gene in two families sharing HPO terms for macrothrombocytopenia and hearing 
loss [20].  
 
Ongoing gene discovery analyses are currently in progress for inherited platelet 
function disorders, which are likely to be more prevalent than platelet number 
disorders, but have proven more difficult to associate with causal variants in single 
genes. In part this reflect practical difficulties for many clinical centres in 
unambiguously defining which platelet pathway is defective using laboratory tests. 
However, systematic analyses of platelet function disorder patient cohorts by 
consortia such as the UK GAPP group using standardised light transmission 
aggregation and ATP secretion assays has successfully delineated specific 
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subgroups of platelet function disorders, including the major subgroups of Gi-
pathway and non-syndromic dense granule secretion defects [21]. Careful analysis 
of NGS data from these sub-groups is expected to expand the repertoire of new IPD 
disorders defined at genetic level. 
 
Next generation sequencing as mainstream for genetic diagnosis of IPD 
The increasing accessibility of NGS, paralleled by the development of 
comprehensive population databases and statistical genetics techniques to enable 
detection of causal variants, is now transforming genetic diagnostic practice. This 
vision is a core objective for pioneering initiatives such as the UK National Health 
Service 100,000 Genomes project (www.genomicsengland.co.uk) which aims to 
perform WGS analysis of 100,000 DNA samples from UK rare disease and cancer 
patients by the end of 2018 and to introduce WGS into mainstream healthcare. This 
impetus promises to revolutionise our approach to genetic diagnosis in IPD and 
heralds the way for genomic medicine in all bleeding disorders.  
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Platelet Function Disorder* Genes Non-hematological manifestations 
Arthrogryposis, renal dysfunction and cholestasis 1 and 2 
(#208085, #613404) VPS33B; VIPAS39 Arthrogryposis, renal dysfunction, cholestasis 
Bernard-Soulier syndrome (#231200) GP1BA; GP1BB; GP9 None 
Chediak-Higashi syndrome (#214500) LYST Partial albinism, impaired phagocytosis 
Deficiency of phospholipase A2, group IVA (no #) PLA2G4A None 
Dense granule abnormalities (no #) NBEA None 
Familial haemophagocytic lymphohistiocytosis type 5 
(#613101) 
STXBP2 None 
Ghosal hematodiaphyseal dysplasia (#231095) TBXAS1 Skeletal abnormalities 
Glanzmann thrombasthenia (#273800) ITGA2B; ITGB3 None 
Hermansky-Pudlak syndromes 1-9 (#203300, #608233, 
#614072, #614073, #614074, #614075, #614076, 
#614077, #614171) 
HPS1; AP3B1; HPS3; HPS4; HPS5; 
HPS6; DTNBP1; BLOC1S3; BLOC1S6 
Oculocutaneous albinisim, pulmonary fibrosis, 
colitis (dependent on subtype) 
Leucocyte integrin adhesion deficiency, type III (#612840) FERMT3 None 
PAR4 defect (no #) F2RL3 None 
Platelet-type bleeding disorder 8 (#609821) P2RY12 None 
Platelet-type bleeding disorder 11 (#614201) GP6 None 
Platelet-type bleeding disorder 13 (#614009) TBXA2R None 
Platelet-type bleeding disorder 18 (#615888) RASGRP2 None 
Quebec platelet disorder (#601709) PLAU None 
Scott syndrome (#262890) ANO6 None 
  
Table 1: Example disorders of platelet function defined at gene level. Disorder names are according to Online Mendelian Inheritance In 
Man nomenclature (http://www.ncbi.nlm.nih.gov/omim) with phenotype reference numbers where appropriate.  
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Platelet Number Disorders* Genes Non-hematological manifestations 
Amegakaryocytic thrombocytopenia with radio-ulnar synostosis 1 and 2 
(#605432, #616738) 
HOXA11, 
MECOM Skeletal abnormalities 
Autosomal dominant thrombocytopenia 2 (#188000) ANKRD26 None 
Autosomal dominant thrombocytopenia 4 (#612004) CYCS None 
Congenital amegakaryocytic thrombocytopenia (#604498) MPL None 
Dominant macrothrombocytopenia and hearing loss (no #) DIAPH1 Sensorineural hearing impairment 
Familial platelet disorder with associated myeloid malignancy (#601399) RUNX1 None 
Gray platelet syndrome (#139090) NBEAL2 None 
Inherited thrombocytopenia with early onset myelofibrosis (no #) SRC Skeletal abnormalities, dysmorphic facies 
Inherited thrombocytopenia with excessive bleeding (no #) SLFN14 None 
Macrothrombocytopenia (no # for isolated platelet phenotype) FLNA Periventricular nodular heterotopia, otopalatodigital syndrome  
May-Hegglin anomaly and other MYH9-related disorders (#155100, 
#153640, #153650, #605249) MYH9 Cataract, renal dysfunction, sensorineural hearing impairment 
Paris-Trousseau type thrombocytopenia and Jacobson syndrome 
(#188025, #147791) FLI1 
Multiple features including developmental delay, skeletal 
abnormalities, congenital cardiac defects 
Platelet-type bleeding disorder 15 (#615193) ACTN1 None 
Platelet-type bleeding disorder 17 (#187900) GFI1B None 
Pseudo-von Willebrand disease (#177820) GP1BA None 
Stormorken syndrome (#185070) STIM1 Myopathy, mioisis, asplenia, ichthyosis 
Thrombocytopenia 5 (#616216) ETV6 Solid organ malignancy 
Thrombocytopenia absent radius syndrome (#274000) RBM8A Skeletal abnormalities, congenital cardiac defects 
TUBB1-related autosomal dominant macrothrombocytopenia (#613112) TUBB1 None 
Wiskott-Aldrich syndrome (#301000) WAS Immune deficiency, eczema  
 
Table 2: Example disorders of platelet number defined at gene level. * Disorder names are according to Online Mendelian Inheritance In 
Man nomenclature (http://www.ncbi.nlm.nih.gov/omim) with phenotype reference numbers where appropriate. 
